Patents Issued in April 18, 2023
-
Patent number: 11629139Abstract: Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g.Type: GrantFiled: September 10, 2018Date of Patent: April 18, 2023Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.Inventors: James Morgan Cunningham, Hu Liu, Ye Tian, Katie Kyungae Lee
-
Patent number: 11629140Abstract: An organic compound is described. An organic electroluminescence device comprises the organic compound, as a host of an emissive layer, or as a hole blocking layer. The organic compound may increase a half-life or current efficiency of the organic electroluminescence device. The organic compound may lower a driving voltage of the organic electroluminescence device. The mentioned organic compound may have the following formula: The same definition as described in the present invention.Type: GrantFiled: August 6, 2019Date of Patent: April 18, 2023Assignee: LUMINESCENCE TECHNOLOGY CORP.Inventors: Feng-Wen Yen, Li-Chieh Chuang
-
Patent number: 11629141Abstract: The compounds of the present invention are represented by the following compounds having Formula (I): where the substituents R, R1-R5, k, m, n, and q are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders, infectious disease, or for providing immunosuppression for transplanted organs or tissues.Type: GrantFiled: February 17, 2021Date of Patent: April 18, 2023Assignee: CORNELL UNIVERSITYInventors: Gang Lin, Carl Nathan, Pradeep K. Singh, Lei Shi, Laura Kirkman
-
Patent number: 11629142Abstract: Disclosed is a novel organic electroluminescent compound represented by Formula (I): The organic electroluminescent compound is employed as a material for at least one organic layer of an organic electroluminescent device such as a light emitting layer, a hole transport layer, an electron transport layer, an electron blocking layer, and/or a capping layer, achieving excellent luminescent properties (including high luminous efficiency and quantum efficiency) of the device. Also disclosed is an organic electroluminescent device including the organic electroluminescent compound.Type: GrantFiled: March 13, 2020Date of Patent: April 18, 2023Assignee: P&H TECH CO., LTD.Inventors: Seo-Yong Hyun, Seok-Keun Yoon
-
Patent number: 11629143Abstract: Provided herein are protein kinase inhibitors, which, in one aspect are selective inhibitors of HipK4. Pharmaceutical compositions and medical uses for the disclosed inhibitors are also provided.Type: GrantFiled: September 30, 2021Date of Patent: April 18, 2023Assignee: VIBLIOME THERAPEUTICS, LLCInventors: Gary A. Flynn, Ashok Bajji, Khoi Huynh
-
Patent number: 11629144Abstract: Disclosed in the present invention are a crystal form of monomethanesulfonate of a deuterated 3-(4,5-substituted aminopyrimidine)phenyl compound as represented by formula I, and a preparation method therefor. The crystal form is highly stable, can be used for treatment or prevention of diseases or conditions by means of epidermal growth factor receptors (EGFRs) in some mutation forms, can effectively inhibit the growth of a variety of tumor cells, and have an inhibiting effect on other proteases of EGFR and Her families, and thus can be used for preparing antitumor drugs.Type: GrantFiled: March 15, 2019Date of Patent: April 18, 2023Assignee: NANJING CHUANGTE PHARMACEUTICAL TECHNOLOGY CO., LTDInventors: Yongqiang Zhu, Yang Yang, Ou Hai, Zhaogang Liu, Chao Feng
-
Patent number: 11629145Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the invention.Type: GrantFiled: October 24, 2017Date of Patent: April 18, 2023Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.Inventors: Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, Lucian V. Dipietro, Elizabeth H. Kelley, André Lescarbeau, Mark Andrew Murcko, Levi Charles Thomas Pierce, Kelley C. Shortsleeves, W. Patrick Walters, Sathesh Bhat, Eric Therrien, Markus Kristofer Dahlgren
-
Patent number: 11629146Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.Type: GrantFiled: November 28, 2017Date of Patent: April 18, 2023Assignee: PRAXIS PRECISION MEDICINES, INC.Inventors: Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
-
Patent number: 11629147Abstract: The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.Type: GrantFiled: September 22, 2020Date of Patent: April 18, 2023Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.Inventors: Qingbei Zeng, Changhe Qi, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
-
Patent number: 11629148Abstract: The present disclosure relates to substituted pyrrollo[3,4-D]imidazoles as JAK inhibitor compounds and uses thereof. Specifically, the present disclosure discloses a compound represented by formula (I), optical isomer thereof, geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof. The present disclosure also relates to the application of the compounds in the treatment of JAK-related diseases or disorders.Type: GrantFiled: August 24, 2021Date of Patent: April 18, 2023Assignee: HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Liang Lu, Hai Huang, Longzheng Zhang, Saisai Zhao, Jixuan Zhang
-
Patent number: 11629149Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.Type: GrantFiled: February 26, 2019Date of Patent: April 18, 2023Assignee: Novartis AGInventors: Maxime Dauphinais, Rama Jain, Dennis Christofer Koester, James R. Manning, Vanessa Marx, Daniel Poon, Lifeng Wan, Xiaojing Michael Wang, Aregahegn Yifru, Qian Zhao
-
Patent number: 11629150Abstract: This invention is in the area of synthesizing pyrimidine-based compounds useful in the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.Type: GrantFiled: December 14, 2020Date of Patent: April 18, 2023Assignee: G1 Therapeutics, Inc.Inventors: Alexander Smith, Hannah S. White, Francis Xavier Tavares, Sergiy Krasutsky, Jian-Xie Chen, Roberta L. Dorrow, Hua Zhong
-
Patent number: 11629151Abstract: Provided is a synthetic intermediate for the preparation of photochromic indolenaphthopyran compounds having the core skeletal structure of Formula (I): wherein m is 0 to 4, n is 0 to 4, R1 and R2 are each independently hydroxyl, cyano, (meth)acrylate, amino, halo, substituted or unsubstituted alkyl, boronic ester, boronic acid, polyether, polyester, polycarbonate, polyurethane, substituted or unsubstituted aryl, substituted or unsubstituted heterocycloaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted arylthio, ketone, aldehyde, ester, carboxylic acid, carboxylate, amide, carbonate, carbamate, urea, siloxane, alkoxysilane, or polysiloxane; R3 is substituted or unsubstituted 2-pyridyl or substituted or unsubstituted 2-quinolyl; and R4 is hydrogen, substituted or unsubstituted alkyl, alkoxymethyl, substituted or unsubstituted silyl, or acyl.Type: GrantFiled: December 21, 2018Date of Patent: April 18, 2023Assignee: Transitions Optical, Ltd.Inventors: Ryan Stayshich, Robert W. Walters
-
Patent number: 11629152Abstract: A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: (wherein, L1 and L2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).Type: GrantFiled: March 29, 2019Date of Patent: April 18, 2023Assignee: KYOWA KIRIN CO., LTD.Inventors: Kenji Uchida, Ryohei Kawai, Keisuke Yamamoto, Toshimi Kanai, Hideo Ikota, Takashi Imaeda, Kei Yoshida
-
Patent number: 11629153Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.Type: GrantFiled: December 29, 2020Date of Patent: April 18, 2023Assignee: Celgene CAR LLCInventors: Jianxin Han, Lianfeng Huang, Uday Jain, Ying Li, John Malona, Kevin Molter, Chittari Pabba, Alexander L. Ruchelman, Jean Xu, Daozhong Zou
-
Patent number: 11629154Abstract: The present invention provides a compound which has an effect of inhibiting amyloid ßproduction, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid ßproteins. A compound of Formula (I) wherein R3 is each independently alkyl optionally substituted with halogen, cyano, alkyloxy, haloalkyloxy or non-aromatic carbocyclyl, or the like; t is integer from 0 to 3; R5 is a hydrogen atom or halogen; R6 is selected from the group consisting of a hydrogen atom, halogen, and substituted or unsubstituted alkyl; ring B is a substituted or unsubstituted pyrazine or the like; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 25, 2019Date of Patent: April 18, 2023Assignee: SHIONOGI & CO., LTD.Inventors: Genta Tadano, Shinji Suzuki, Ken-ichi Kusakabe
-
Small molecule antagonist compound TAC5 series having toll-like receptor 3/7/8/9 inhibitory function
Patent number: 11629155Abstract: A small molecule antagonist compound having a toll-like receptor 3/7/8/9 inhibitory function and its use in inhibiting TLR7, TLR8, TLR9 and TLR3 are disclosed. A novel compound expressed by TAC5 and TAC5-a, TAC5-c, TAC5-d or TAC5-e which are derivatives thereof not only prevents TNF? secretion, NFkB activation, IkB degradation and MAPKs phosphorylation induced by poly(I:C) (TLR3 agonist), IMQ (TLR7 agonist), CL075 (TLR7/8 agonist), R848 (TLR7/8 agonist), TL8 (TLR8 agonist) or CpG ODN (TLR9 agonist), but also inhibits generation of inflammatory cytokine, and thus is highly advantageous for preventive or therapeutic use for TLR3/7/8/9-related autoimmune diseases and inflammatory diseases including systemic lupus erythematosus, psoriasis and the like.Type: GrantFiled: May 20, 2019Date of Patent: April 18, 2023Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Sangdon Choi, Eunha Kim -
Patent number: 11629156Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).Type: GrantFiled: March 16, 2021Date of Patent: April 18, 2023Assignee: Eli Lilly and CompanyInventors: Renato Alejandro Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Raymond Gilmour, Patric James Hahn, Zoran Rankovic
-
Patent number: 11629157Abstract: A series of 8-(bisphenylethynyl)-ester flexible multiple ring-containing fluoroboron pyrrole liquid crystal dyes are synthesized by introducing a diphenylethynyl rigid structure at position 8 of a boron-dipyrromethene core via a Sonogashira coupling reaction, and a flexible multiple ring such as bicyclohexane, or cholesterol is connected to the biphenylethynyl via an esterification reaction. The dye compounds all have maximum emission wavelengths in methylene chloride concentrated around 525 nm, present green fluorescence, and show good dichroic colour ratios and ordered parameters in E7 liquid crystal. The liquid crystal compounds are in a liquid crystal intermediate phase within the range of 100-280° C., and may be used for manufacturing liquid crystal display products, especially as guest dyes for guest-host mode liquid crystal displays. The response time can be improved and a rapid response effect achieved when the compounds are added to E7 liquid crystal and used for a guest-host display mode.Type: GrantFiled: January 22, 2020Date of Patent: April 18, 2023Assignee: DALIAN UNIVERSITY OF TECHNOLOGYInventors: Xiaolian Li, Rouchen Pan
-
Patent number: 11629158Abstract: Provided is a method for producing a cyclic polysilane compound from a silane monomer compound in one-pot approach. The method for producing a cyclic polysilane compound according to an embodiment of the present invention includes a first step of adding and reacting a silane monomer compound in a liquid mixture of a sodium dispersion and a solvent; and a second step of adding an aromatic hydrocarbon to a reaction solution of the first step and heating and refluxing.Type: GrantFiled: March 7, 2019Date of Patent: April 18, 2023Assignee: KUREHA CORPORATIONInventors: Ryota Naito, Hiraku Tohmiya
-
Patent number: 11629159Abstract: This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.Type: GrantFiled: August 11, 2022Date of Patent: April 18, 2023Assignee: Compass Pathfinder LimitedInventors: Derek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, Hemant Kashinath Patil, David E. Nichols
-
Patent number: 11629160Abstract: Described herein are corrole-based frameworks and methods for making the same. The corrole-based frameworks have unique structural and physical properties, which lends them to be versatile in a number of different applications and uses such as in gas storage/separation, proton conduction, biomedicine, sensing, and catalysis. In one aspect, the corrole-based frameworks are organic frameworks. In other aspects, the corrole-based frameworks are metal-organic frameworks.Type: GrantFiled: August 20, 2020Date of Patent: April 18, 2023Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Shengqian Ma, Yanming Zhao
-
Patent number: 11629161Abstract: Intermediate compounds are described herein and which are used to manufacture a crystalline compound 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene L-proline monohydrate.Type: GrantFiled: November 30, 2021Date of Patent: April 18, 2023Inventors: Matthias Eckhardt, Monika Brink, Frank Himmelsbach, Stefan Sahli, Chutian Shu, Xiao-Jun Wang, Beat Theodor Weber, Bing-Shiou Yang
-
Patent number: 11629162Abstract: A number of triterpene saponin variants with different modifications on their central glycosyl ester linkage are described. Also described are methods of making and method of using such triterpene saponin variants.Type: GrantFiled: December 19, 2016Date of Patent: April 18, 2023Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Derek S. Tan, David Y. Gin, William E. Walkowicz, Alberto Fernandez-Tejada, Govindaswami Ragupathi
-
Patent number: 11629163Abstract: Provided herein are efficient and scalable methods for the synthesis of nicotinamide riboside from riboside triacetate. Also provided are compositions comprising nicotinamide riboside, and therapeutic methods employing nicotinamide riboside.Type: GrantFiled: June 29, 2018Date of Patent: April 18, 2023Assignee: Elysium Health, Inc.Inventors: Eric Marcotulli, Dan Alminana, Ryan Dellinger, Mark Morris, Rajesh Thamatam
-
Patent number: 11629164Abstract: This invention relates to a prodrug of the monophosphate nucleotide of the well-known oncology drug gemcitabine. Specifically, it relates to gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate when present as a single phosphate diastereoisomer and, in particular, it relates to the (S)-phosphate diastereoisomer which offers a remarkable and unexpected increase in solubility relative to the (R)-diastereoisomer. The (S)-phosphate epimer is also preferentially taken up into cyclodextrin solutions over the (R)-diastereoisomer.Type: GrantFiled: May 4, 2020Date of Patent: April 18, 2023Assignee: NuCana plcInventors: Hugh Griffith, Christopher McGuigan, Magdalena Slusarczyk, Michaela Serpi, Valentina Ferrari
-
Patent number: 11629165Abstract: Molecule having the structural formula (I): (I) for use as targeting probe of translating ribosomes and ribosome-interacting proteins.Type: GrantFiled: July 8, 2019Date of Patent: April 18, 2023Assignee: IMMAGINA BIOTECHNOLOGY S.R.L.Inventors: Massimiliano Clamer, Luca Minati
-
Patent number: 11629166Abstract: The invention relates to compounds, compositions and polymers comprising a first component adapted to promote germination of Clostridium difficile (C. diff) and a second component which acts as an antimicrobial agent. Said compounds, compositions and polymers are useful for destroying C. diff where conventional antimicrobial agents are unsuccessful. The compositions can be formulated as coating or materials which actively destroy C. diff which come into contact with it. The germination promotion is induced by bile salts. The invention also relates to the use of such materials as a treatment for C. diff associated diseases and toxic megacolon.Type: GrantFiled: December 23, 2019Date of Patent: April 18, 2023Assignee: Aston UniversityInventors: Daniel Lee Rathbone, Tony Worthington, Sahar Al-Malaika, Matthew Justin Hird, Alexandria Rose Quayle
-
Patent number: 11629167Abstract: The present disclosure relates to Betulastatin compounds, pharmaceutical compositions and kits comprising such compounds, and methods for using such compounds or pharmaceutical compositions.Type: GrantFiled: November 9, 2018Date of Patent: April 18, 2023Assignee: Arizona Board of Regents on behalf of Arizona State UniversityInventors: George R. Pettit, Noeleen Melody
-
Patent number: 11629168Abstract: The invention aims to provide an immunoglobulin-binding protein having improved chemical stability, especially stability against alkali. The object can be achieved by improving stability against alkali by substituting an amino acid residue(s) at a particular position(s) in an immunoglobulin-binding domain such as domain C of protein A derived from a bacterium belonging to the genus Staphylococcus, to another/other particular amino acid residue(s).Type: GrantFiled: November 8, 2018Date of Patent: April 18, 2023Assignee: TOSOH CORPORATIONInventors: Naoki Yamanaka, Yukie Uchida, Yosuke Terao
-
Patent number: 11629169Abstract: The present invention relates to use of peptides as a therapeutic agent, wherein it has been confirmed that the peptides of the present invention significantly inhibit the activity of T cells and the differentiation of T helper 17 cells (Th17 cells), which are associated with autoimmune disease, and have remarkable effects of treating and improving arthritis in an animal model of arthritis. Therefore, the peptides may be used as an active ingredient in therapeutic agents for various autoimmune diseases such as bone disease, inflammatory disease or rheumatoid arthritis.Type: GrantFiled: September 14, 2018Date of Patent: April 18, 2023Assignee: KINE SCIENCES CO., LTD.Inventors: Dae Ho Cho, Kyung Eun Kim, Myun Soo Kim, Sun Young Park, Hee Young Jung
-
Patent number: 11629170Abstract: The present description relates to methods for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell. The methods involve contacting the cell with the polypeptide cargo in the presence of a peptide shuttle agent at a concentration sufficient to increase the polypeptide cargo's transduction efficiency. Also described here are parameters that may be used in the rational design of such synthetic peptide shuttle agents, peptide shuttle agents that satisfy one or more of these design parameters, as well as methods and compositions relating to the use of the synthetic peptide shuttle agents for delivery of a variety of polypeptide cargos (such as transcription factors, antibodies, CRISPR-associated nucleases and functional genome editing complexes) from an extracellular space to the cytosol and/or nucleus of target eukaryotic cells. Applications and targets for genome-editing NK cells for improved immunotherapy are also described.Type: GrantFiled: October 11, 2017Date of Patent: April 18, 2023Assignee: FELDAN BIO INC.Inventors: Thomas Del'Guidice, Jean-Pascal Lepetit-Stoffaes, David Guay
-
Patent number: 11629171Abstract: Beta-hairpin peptidomimetics of the general formula (I), and pharmaceutically acceptable salts thereof, with P, X, Q., and optionally L being elements as defined in the description and the claims, have Gram-negative antimicrobial activity to e.g. inhibit the growth or to kill microorganisms such as Klebsiella pneumoniae and/or Acinetobacter baumannii and/or Escherichia coli and/or Pseudomonas aeruginosa and/or Enterobacter cloacae. They can be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: GrantFiled: November 12, 2018Date of Patent: April 18, 2023Assignee: Spexis AGInventors: Daniel Obrecht, Anatol Luther, Francesca Bernardini, Glenn E. Dale, Nicolas Desjonqueres, Emile Brabet, Grégory Upert
-
Patent number: 11629172Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.Type: GrantFiled: December 19, 2019Date of Patent: April 18, 2023Assignee: Pfizer Inc.Inventors: Philip Ralph Dormitzer, Ye Che, Xiaoyuan Sherry Chi, Seungil Han, Kyle Paul Heim, Thomas Richard Jones, Yuhang Liu, Xiayang Qiu, Xinzhen Yang, Xiaojie Yao, Matthew Curtis Griffor, Jennifer Anne Nicki
-
Patent number: 11629173Abstract: In alternative embodiments, provided are compositions and methods for making a chimeric polypeptide comprising an S-layer polypeptide and a heterologous polypeptide or peptide. In alternative embodiments, the compositions and methods comprise recombinantly engineering a methylotrophic or methanotrophic bacteria to recombinantly express a chimeric polypeptide comprising an S-layer polypeptide and a heterologous polypeptide or peptide. Also provided are compositions and methods for displaying or immobilizing proteins on a methanotrophic S-layer. In alternative embodiments, provided are compositions and methods comprising recombinant methylotrophic or methanotrophic bacteria comprising assembled or self-assembled recombinant or isolated chimeric S-layer polypeptides. In alternative embodiments, provided are compositions and methods using recombinant methylotrophic or methanotrophic bacteria, optionally a Methylomicrobium alcaliphilum, optionally a M. alcaliphilum sp.Type: GrantFiled: August 29, 2018Date of Patent: April 18, 2023Assignee: San Diego State University (SDSU) FoundationInventors: Marina Kalyuzhnaya, Oleksandr Demidenko
-
Patent number: 11629174Abstract: Disclosed is a high-throughput transcriptional assay format in Actinomycete bacteria, and Streptomyces spp. in particular, that leverages eGFP, inserted both at a neutral site and inside the biosynthetic cluster of interest, as a read-out for secondary metabolite synthesis. Using this approach, a silent gene cluster in Streptomyces albus J1074 was induced. The cytotoxins etoposide and ivermectin were revealed as potent inducers, allowing the isolation and structural characterization of nearly 20 novel small molecule products of the chosen cluster. One of these molecules is a novel antifungal, while several others inhibit a cysteine protease implicated in cancer. Studies addressing the mechanism of induction by the two elicitors led to the identification of a pathway-specific transcriptional repressor that silences the gene cluster under normal growth conditions.Type: GrantFiled: May 11, 2018Date of Patent: April 18, 2023Assignee: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Mohammad R. Seyedsayamdost, Fei Xu, Kyuho Moon, Behnam Nazari
-
Patent number: 11629175Abstract: The invention relates to a method for preparing PHFs-like Tau aggregates and to a method for identifying compounds that are inhibitors of Tau protein aggregation, blockers of Tau seeding and propagation, and imaging agents that specifically bind PHF.Type: GrantFiled: April 29, 2019Date of Patent: April 18, 2023Assignee: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)Inventors: Hilal A. Lashuel, Nadine Ait-Bouziad
-
Patent number: 11629176Abstract: A method of obtaining cell derived vesicles comprising an active wild-type p53 is disclosed. The method comprising: (i) isolating cell derived vesicles from a biological sample comprising cells; and (ii) treating the cell derived vesicles with a DNA damaging agent, or the method comprising: (i) treating cells with a DNA damaging agent; and (ii) isolating cell derived vesicles from a biological sample comprising the cells. A proteinaceous preparation comprising cell derived vesicles and a pharmaceutical composition comprising the proteinaceous preparation are also disclosed. Methods of treating a disease, disorder or condition associated with a mutant or a nonfunctional p53 protein and methods of inducing apoptosis of a target cell comprising a mutant or a nonfunctional p53 protein are also disclosed.Type: GrantFiled: March 21, 2018Date of Patent: April 18, 2023Assignee: Exoprother Medical Ltd.Inventors: Alexander Tendler, Lana Volokh
-
Patent number: 11629177Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: August 26, 2022Date of Patent: April 18, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Colette Song, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
-
Patent number: 11629178Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.Type: GrantFiled: March 1, 2022Date of Patent: April 18, 2023Assignee: DEKA BIOSCIENCES, INC.Inventor: John Mumm
-
Patent number: 11629179Abstract: The present invention relates to TWEAK-receptor agonists for use in the treatment of a cancer, wherein the TWEAK-receptor agonist is combined with immunotherapy of the cancer. The TWEAK-receptor agonist preferably is a multivalent ligand that causes clustering of TWEAK-receptors at the cell surface. A suitable TWEAK-receptor agonist is an agonistic anti-Fn14 antibody. The TWEAK-receptor agonist and immunotherapy be can further be combined with a SMAC mimetic in the treatment of cancer. The TWEAK-receptor agonist is useful, optionally in combination with a SMAC mimetic, to prevent resistance of a cancer to immunotherapy and/or to treat a cancer comprising tumor cells that are resistant to immunotherapy.Type: GrantFiled: June 28, 2019Date of Patent: April 18, 2023Assignee: Stichting Het Nederlands Kanker Instituut—Antoni van Leeuwenhoek ZiekenhuisInventors: Daniel Simon Peeper, Thomas Kuilman, David Willem Vredevoogd
-
Patent number: 11629180Abstract: The present invention relates to a bifunctional angiogenesis inhibitor, which has VEGF inhibitory activity and FGF inhibitory activity, and can inhibit VEGF and FGF dual factors-induced or high glucose-induced cell proliferation, cell migration, and/or lumen formation. The present invention also relates to the use of the bifunctional angiogenesis inhibitor in inhibiting retinal angiogenesis, such as diabetic retinopathy, age-related macular degeneration and the like.Type: GrantFiled: December 4, 2019Date of Patent: April 18, 2023Assignee: Remegen Co., Ltd.Inventors: Jing Jiang, Jianmin Fang, Xuejing Luan, Xuejing Yao, Ling Wang
-
Patent number: 11629181Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.Type: GrantFiled: June 23, 2022Date of Patent: April 18, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Kurt Swanson, Philip R. Dormitzer
-
Patent number: 11629182Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.Type: GrantFiled: December 16, 2021Date of Patent: April 18, 2023Assignee: Research Institute of Nationwide Children's HospitalInventors: Steven D. Goodman, Lauren O. Bakaletz
-
Patent number: 11629183Abstract: Disclosed herein are monoclonal antibodies targeting specific tau epitopes, particularly, microtubule binding domain region 2 or region 4. Also disclosed herein are antibodies or antigen binding fragments thereof that specifically recognize a tau epitope consisting of the amino acid sequence of SEQ ID NO: 9 or 11. Also disclosed herein are methods of detecting tau protein in a subject, comprising performing an assay using the antibodies or antigen binding fragments thereof on the subject or on a biological sample obtained from the subject. Assay kits containing the disclosed antibodies are also provided. Further, methods of treating or preventing a tauopathy in a subject by administering to the subject tau antibodies or antigen-binding fragments thereof are provided.Type: GrantFiled: December 28, 2018Date of Patent: April 18, 2023Assignee: University of Florida Research Foundation, Inc.Inventors: Benoit Giasson, Todd Eliot Golde, Cara Louise Croft, Yona Levites, Brenda Dawn Moore
-
Patent number: 11629184Abstract: This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind Calcitonin Gene Related Peptide (CGRP). These anti-CGRP antibodies, or antigen-binding fragments thereof, have a high affinity for CGRP, function to inhibit CGRP, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., a human) and can be used to treat CGRP-associated disorders, while avoiding the adverse side effects associated with the current CGRP antagonist therapies.Type: GrantFiled: February 23, 2019Date of Patent: April 18, 2023Assignee: REMD Biotherapeutics, Inc.Inventors: Frank J Calzone, John Zhang
-
Patent number: 11629185Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.Type: GrantFiled: December 18, 2020Date of Patent: April 18, 2023Assignees: NOVO NORDISK A/S, UNIVERSITY HEALTH NETWORKInventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
-
Patent number: 11629186Abstract: Anti-CCL8 antibodies and antigen binding fragments thereof are described. Antibodies and fragments thereof can be used for prevention of migration of breast cancer cells. Methods include delivery of an anti-CCL8 antibody or an antigen binding fragment thereof to an area including the breast cancer cells, e.g., delivery to a subject in need thereof in an effective amount.Type: GrantFiled: June 8, 2020Date of Patent: April 18, 2023Assignee: University of South CarolinaInventors: Hippokratis Kiaris, Eleni Farmaki, Ioulia Chatzistamou, Vimala Kaza
-
Patent number: 11629187Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.Type: GrantFiled: June 22, 2021Date of Patent: April 18, 2023Assignee: The Johns Hopkins UniversityInventors: Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian
-
Patent number: 11629188Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.Type: GrantFiled: February 27, 2020Date of Patent: April 18, 2023Assignee: ONCOC4, INC.Inventors: Yang Liu, Pan Zheng, Martin Devenport